We found that the six top-ranked features, mapping to five distinct gene products (IDHC, SERA, IGJ, EF2 and KCRB; pink bars in Fig. 4b) showed the best performance to discriminate all prostate cancer patients (pT2 and pT3) from biopsy-verified normal controls. This evidence concerns the gene PHGDH and prostate carcinoma.